Effect of Plasma Fibrinogen Levels on the Risk of Stroke in Patients with Type 2 Diabetes: A Systematic Review

Abstract

Aims In this systematic review, we assessed the literature on the association between fibrinogen levels and stroke in patients with type 2 diabetes (T2D).

Methods MEDLINE and Ovid searches of English reports were performed on the relation between fibrinogen, stroke, and T2D in humans. The search was completed on May 4, 2023. Studies were eligible when T2D patients ≥18 years had stroke confirmed by computed tomography or magnetic resonance imaging, plasma fibrinogen was measured, and a relation between fibrinogen and stroke in T2D patients was reported. Screening of reports and extraction of data were done independently by two authors, and study quality was assessed by predefined issues.

Results Five studies of different designs were included. Three studies reported on significantly increased fibrinogen levels in T2D patients with stroke compared with T2D patients without stroke. Two studies did not observe a significant association between fibrinogen levels and stroke risk.

Conclusion No consistent association was observed between fibrinogen levels and risk of stroke in T2D patients. Due to differences in study design, low sample size, and poorly defined study participants, larger and better-defined studies are needed to elucidate the role of fibrinogen as a stroke risk marker in T2D patients.

Keywords

fibrinogen - type 2 diabetes - ischemic stroke - systematic review

Publikationsverlauf

Eingereicht: 29. August 2023

Angenommen: 01. November 2023

Artikel online veröffentlicht:
30. Januar 2024

• References

• 1 Tsao CW, Aday AW, Almarzooq ZI. et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation 2022; 145 (08) e153-e639
• 2 Feigin VL, Stark BA, Johnson CO. et al; GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021; 20 (10) 795-820
• 3 Sarwar N, Gao P, Seshasai SRK. et al; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375 (9733) 2215-2222
• 4 Shou J, Zhou L, Zhu S, Zhang X. Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis 2015; 24 (09) 1961-1968
• 5 Sun H, Saeedi P, Karuranga S. et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183: 109119
• 6 Bembde AS. A study of plasma fibrinogen level in type-2 diabetes mellitus and its relation to glycemic control. Indian J Hematol Blood Transfus 2012; 28 (02) 105-108
• 7 La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol 2019; 26 (Suppl. 02) 15-24
• 8 Aung K, Lorenzo C, Hinojosa MA, Haffner SM. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J Clin Endocrinol Metab 2014; 99 (02) 462-468
• 9 Patterson R, McNamara E, Tainio M. et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol 2018; 33 (09) 811-829
• 10 Li M, Xu Y, Wan Q. et al. Individual and combined associations of modifiable lifestyle and metabolic health status with new-onset diabetes and major cardiovascular events: The China Cardiometabolic Disease and Cancer Cohort (4C) Study. Diabetes Care 2020; 43 (08) 1929-1936
• 11 Beamer N, Coull BM, Sexton G, de Garmo P, Knox R, Seaman G. Fibrinogen and the albumin-globulin ratio in recurrent stroke. Stroke 1993; 24 (08) 1133-1139
• 12 Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311 (08) 501-505
• 13 Jain A, Gupta HL, Narayan S. Hyperfibrinogenemia in patients of diabetes mellitus in relation to glycemic control and urinary albumin excretion rate. J Assoc Physicians India 2001; 49: 227-230
• 14 Fuller JH, Keen H, Jarrett RJ. et al. Haemostatic variables associated with diabetes and its complications. BMJ 1979; 2 (6196) 964-966
• 15 Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2017; 37 (03) e13-e21
• 16 Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012; 34 (01) 43-62
• 17 Dunn EJ, Ariëns RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48 (06) 1198-1206
• 18 Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol 2017; 16 (01) 34
• 19 Pieters M, Covic N, van der Westhuizen FH. et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost 2008; 99 (04) 691-700
• 20 Page MJ, Moher D, Bossuyt PM. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372: n160
• 21 Hankey GJ, Anderson NE, Ting RD. et al. Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study. J Neurol Neurosurg Psychiatry 2013; 84 (03) 281-287
• 22 Asakawa H, Tokunaga K, Kawakami F. Comparison of risk factors of macrovascular complications. Peripheral vascular disease, cerebral vascular disease, and coronary heart disease in Japanese type 2 diabetes mellitus patients. J Diabetes Complications 2000; 14 (06) 307-313
• 23 Ali MH, Sen K, Ghosh K. et al. High fibrinogen level in patients with type 2 DM and ischemic cerebrovascular accident - an experience from a tertiary care hospital of Eastern India. J Indian Med Assoc 2020; 118: 25-27
• 24 Bots ML, Elwood PC, Salonen JT. et al. Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 2002; 56 (Suppl. 01) i14-i18
• 25 Mistry P, Chawla KP, Rai HP, Jaiswal P. Plasma fibrinogen levels in stroke. J Postgrad Med 1990; 36 (01) 1-4
• 26 de Maat MPM, Bertina RM, Haverkate F. Laboratory Techniques in Thrombosis: A Manual. Kluwer Academic Publishers; Dordrecht, The Netherlands: 1999: 79-81
• 27 Sahan M, Sebe A, Acikalin A. et al. Acute-phase reactants and cytokines in ischemic stroke: do they have any relationship with short-term mortality?. Eur Rev Med Pharmacol Sci 2013; 17 (20) 2773-2777
• 28 Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health 2001; 4 (05) 392-400
• 29 O'Donnell MJ, Xavier D, Liu L. et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376 (9735) 112-123
• 30 Boehme AK, Esenwa C, Elkind MSV. Stroke risk factors, genetics, and prevention. Circ Res 2017; 120 (03) 472-495
• 31 de Maat MPM. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann N Y Acad Sci 2001; 936: 509-521
• 32 Madsen TE, Khoury J, Alwell K. et al. Sex-specific stroke incidence over time in the Greater Cincinnati/Northern Kentucky Stroke Study. Neurology 2017; 89 (10) 990-996
• 33 Horn JW, Feng T, Mørkedal B. et al. Obesity and risk for first ischemic stroke depends on metabolic syndrome: the HUNT study. Stroke 2021; 52 (11) 3555-3561
• 34 Friberg L, Rosenqvist M, Lindgren A, Terént A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014; 45 (09) 2599-2605
• 35 Tsang TSM, Petty GW, Barnes ME. et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42 (01) 93-100
• 36 Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015; 14 (04) 377-387
• 37 Del Brutto VJ, Chaturvedi S, Diener HC, Romano JG, Sacco RL. Antithrombotic therapy to prevent recurrent strokes in ischemic cerebrovascular disease: JACC Scientific Expert Panel. J Am Coll Cardiol 2019; 74 (06) 786-803
• 38 Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992; 117 (05) 371-375
• 39 Nenclares P, Gunn L, Soliman H. et al. On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. J Immunother Cancer 2021; 9 (06) 1-8
• 40 Sanossian N, Djabiras C, Mack WJ, Ovbiagele B. Trends in cancer diagnoses among inpatients hospitalized with stroke. J Stroke Cerebrovasc Dis 2013; 22 (07) 1146-1150
• 41 Pennlert J, Eriksson M, Carlberg B, Wiklund PG. Long-term risk and predictors of recurrent stroke beyond the acute phase. Stroke 2014; 45 (06) 1839-1841
• 42 Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957; 17 (04) 237-246
• 43 van der Bom JG, de Maat MPM, Bots ML, Hofman A, Kluft C, Grobbee DE. Seasonal variation in fibrinogen in the Rotterdam Study. Thromb Haemost 1997; 78 (03) 1059-1062
• 44 Varley H, Gowenlock A, Bell M. Practical Clinical Biochemistry. 5 ed. William Heinemann Medical Books Ltd.; London, United Kingdom: 1984: 557